WEB On July 20 2023 Idorsia sold its operating businesses in the Asia Pacific ex-China region to Sosei. WEB Allschwil Switzerland October 24 2023 IDIA today announced its financial results. IDIA today announced its financial results for the first half of 2023. WEB On July 21 2023 Idorsia announced that it has launched a cost reduction initiative with the target to reduce cash-burn at. WEB Allschwil Switzerland September 6 2023 IDIA today announced that it has entered. IDIA today announced its financial results for the first half of 2023. WEB Idorsia announces financial results for the first quarter 2023 QUVIVIQ now the leading branded. IDIA today announced its financial results for the first quarter of 2023..
Globenewswire
WEB On July 20 2023 Idorsia sold its operating businesses in the Asia Pacific ex-China region to Sosei. WEB Allschwil Switzerland October 24 2023 IDIA today announced its financial results. IDIA today announced its financial results for the first half of 2023. WEB On July 21 2023 Idorsia announced that it has launched a cost reduction initiative with the target to reduce cash-burn at. WEB Allschwil Switzerland September 6 2023 IDIA today announced that it has entered. IDIA today announced its financial results for the first half of 2023. WEB Idorsia announces financial results for the first quarter 2023 QUVIVIQ now the leading branded. IDIA today announced its financial results for the first quarter of 2023..
WEB New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology. WEB Allschwil Switzerland March 18 2024 IDIA today announced that it has successfully closed the transaction with Viatris Inc. WEB US FDA approves Idorsias once-daily TRYVIO aprocitentan the first and only endothelin receptor antagonist for the treatment of high. WEB Allschwil Switzerland September 6 2023 IDIA today announced that it has entered into an agreement with Janssen Biotech. 28 2024 PRNewswire -- Viatris Inc VTRS a global healthcare company and Idorsia Ltd SIX..
WEB The company is laying off 300 people predominantly in RD and associated functions according to an announcement Tuesday About 175 other positions were made redundant by. Idorsia the Switzerland-based biotechnology company disclosed Friday a broad cost-cutting initiative that could include as many as 500 layoffs. Up to 500 roles at Idorsia are at risk as the Swiss biotech tries to halve its cash burn while it waits for insomnia. Idorsia weighs layoffs deals pipeline trims to bring cost down Idorsia could cut up to 500 positions in RD and. WEB Idorsia announced Friday morning that it has launched a cost reduction initiative to reign in its cash burn by 50 by early 2024 The Swiss biotech said that up to 500 jobs..
**Idorsia Reports Financial Performance and Business Updates** **Allschwil, Switzerland – October 24, 2023** Idorsia Pharmaceuticals Ltd. (IDIA) today announced its financial results for the first half of 2023. **Financial Highlights** * Revenue reported at CHF 97.0 million * Operating loss of CHF 102.2 million * Net cash position of CHF 1.2 billion **Business Updates** * **Sale of Asia Pacific ex-China Businesses:** On July 20, 2023, Idorsia completed the sale of its operating businesses in the Asia Pacific ex-China region to Sosei. * **Cost Reduction Initiative:** On July 21, 2023, Idorsia announced a cost reduction initiative aimed at reducing cash-burn. * **Strategic Partnership with Sosei:** On September 6, 2023, Idorsia announced a strategic partnership with Sosei to advance the development and commercialization of novel therapies. **Financial Results for First Quarter 2023** Idorsia also announced its financial results for the first quarter of 2023. **Financial Highlights (Q1 2023)** * Revenue reported at CHF 45.6 million * Operating loss of CHF 52.1 million * Net cash position of CHF 1.3 billion **Product Updates** * QUVIVIQ remains the leading branded therapy for Huntington's disease. * Idorsia continues to explore the development of new therapies in its pipeline. "We are pleased to report our financial results for the first half of 2023," said Jean-Paul Clozel, MD, CEO of Idorsia. "We believe our strategic initiatives, including the sale of our Asia Pacific ex-China businesses and the cost reduction initiative, will position us for future growth and profitability."
Delco Today
Comments